OCTIMET Oncology's Series A Round

OCTIMET Oncology raised a round of funding on January 19, 2017.

OCTIMET Oncology has licensed highly selective MET kinase inhibitors from Janssen Pharmaceutica NV and will advance the development of these molecules by employing innovative patient selection and pha…

Articles about OCTIMET Oncology's Series A Round: